|
Sex,
n
(%)
|
|
Male
|
61 (80)
|
29 (54)
|
95 (69)
|
|
Female
|
15 (20)
|
25 (46)
|
42 (31)
|
|
Race/ethnicity,
n
(%)
|
|
White/Caucasian
|
73 (96)
|
53 (98)
|
133 (97)
|
|
Black/African American
|
2 (3)
|
0 (0)
|
2 (1)
|
|
Hispanic/Latino
|
0 (0)
|
1 (2)
|
1 (1)
|
|
Japanese
|
1 (1)
|
0 (0)
|
1 (1)
|
|
Median age, years (range)
|
63.5 (21–84)
|
65.0 (37–80)
|
64.0 (21–84)
|
|
Age group,
n
(%)
|
|
<65 years
|
40 (53)
|
26 (48)
|
71 (52)
|
|
≥65 years
|
36 (47)
|
28 (52)
|
66 (48)
|
|
<75 years
|
71 (93)
|
44 (81)
|
121 (88)
|
|
≥75 years
|
5 (7)
|
10 (19)
|
16 (12)
|
|
Primary tumour type,
n
(%)
|
|
Colon cancer
|
43 (57)
|
36 (67)
|
82 (60)
|
|
Rectal cancer
|
33 (43)
|
18 (33)
|
55 (40)
|
|
Number of metastatic sites,
n
(%)
|
|
1
|
33 (43)
|
23 (43)
|
63 (46)
|
|
2
|
22 (29)
|
19 (35)
|
41 (30)
|
|
≥3
|
21 (28)
|
12 (22)
|
33 (24)
|
|
Location of metastatic sites,
n
(%)
|
|
Liver only
|
28 (37)
|
15 (28)
|
46 (34)
|
|
Liver plus other sites
|
35 (46)
|
25 (46)
|
60 (44)
|
|
Other sites only
|
13 (17)
|
14 (26)
|
31 (23)
|
|
ECOG performance status,
n
(%)
|
|
0
|
43 (57)
|
30 (56)
|
80 (58)
|
|
1
|
30 (39)
|
20 (37)
|
50 (36)
|
|
2
|
3 (4)
|
4 (7)
|
7 (5)
|
|
Mean (SD) PRO scores
|
|
EQ-5D health state index
|
0.81 (0.22)
|
0.80 (0.22)
|
0.81 (0.22)
|
|
EQ-5D overall health rating
|
71.7 (20.1)
|
71.9 (19.6)
|
72.5 (19.8)
|
|
QLQ-C30 global health status
|
64.4 (22.5)
|
65.1 (22.8)
|
65.8 (22.5)
|
